Table 2. Adherence for the 9-month follow-up for each trajectory and therapeutic group.
| Percentage | mean PDC | PDC>75% | ||
|---|---|---|---|---|
| Antiplatelet | Adherent | 66.5 | 96.1 | 97.6 |
| Early gap | 13.8 | 85.8 | 84.7 | |
| Occasional users | 10.0 | 60.9 | 28.0 | |
| Slow decline | 4.5 | 54.6 | 9.2 | |
| Fast decline | 5.2 | 16.4 | 0.0 | |
| Beta-blockers | Adherent | 61.0 | 94.1 | 96.1 |
| Occasional users | 22.9 | 61.0 | 20.6 | |
| Slow decline | 5.8 | 52.4 | 8.6 | |
| Fast decline | 10.2 | 19.3 | 0.6 | |
| ACEI/ARB | Adherent | 66.0 | 92.4 | 91.4 |
| Occasional users | 17.5 | 61.4 | 20.7 | |
| Slow decline | 6.8 | 45.4 | 2.5 | |
| Fast decline | 9.8 | 11.9 | 0.2 | |
| Statins | Adherent | 74.9 | 92.9 | 93.6 |
| Occasional users | 17.5 | 58.9 | 14.5 | |
| Fast decline | 7.6 | 17.5 | 0.0 | |
PDC, percentage of days covered